Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Hernández JL, Lozano FS, Riambau V, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S, Garcia-Alegria J, Garcia-Moll X, Gomez-Doblas JJ, Gonzalez-Juanatey JR, Suarez Fernández C.
Hernández JL, et al.
Drugs Context. 2020 Jul 6;9:2020-5-5. doi: 10.7573/dic.2020-5-5. eCollection 2020.
Drugs Context. 2020.
PMID: 32699549
Free PMC article.
Review.